 | Up a level |
2022
Drilon, A., Subbiah, V., Gautschi, O., Tomasini, P., De Braud, F. G. M., Solomon, B., Tan, D. Shao-Weng, Alonso, G., Wolf, J., Park, K., Goto, K., Soldatenkova, V., Szymczak, S., Barker, S., Puri, T., Lin, A. B., Loong, H. H. F. and Besse, B. (2022). Durability of efficacy and safety with selpercatinib in patients (pts) with RET fusion plus non-small cell lung cancer (NSCLC). Ann. Oncol., 33. S. S43 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Solomon, B. J., Loong, H. H., Summers, Y., Thomas, Z. M., French, P., Lin, B. K., Sashegyi, A., Wolf, J., Yang, J. C-H and Drilon, A. (2022). Correlation between treatment effects on response rate and progression-free survival and overall survival in trials of targeted therapies in molecularly enriched populations. ESMO Open, 7 (2). AMSTERDAM: ELSEVIER. ISSN 2059-7029
2021
Goto, K., Oxnard, G., Tan, Shao-Weng D. S. W., Loong, Ho Fung H., Bauer, T. T., Gainor, J., McCoach, C., Gautschi, O., Besse, B., Cho, B. C., Peled, N., Weiss, J., Kim, Y., Ohe, Y., Horiike, A., Park, K., Huang, X., Olek, E., Subbiah, V, Drilon, A. and Wolf, J. (2021). Selpercatinib (LOXO-292) in patients with RET-Fusion+ non small-cell lung cancer (NSCLC). Pneumologie, 75. S. S42 - 1. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1438-8790
Goto, K., Wolf, J., Elamin, Y., Santini, F., Soldatenkova, V., Sashegyi, A., Lin, A. Bence, Lin, B., Novello, S., Arriola Aperribay, E., Perol, M., Loong, H., Drilon, A., Park, K., Solomon, B. and Zhou, C. (2021). LIBRETTO-431: Selpercatinib in Treatment-Naive Patients with RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC). J. Thorac. Oncol., 16 (3). S. S228 - 2. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1556-1380
Paz-Ares, L., Barlesi, F., Siena, S., Ahn, M-J, Drilon, A., Conley, A., Rolfo, C., Wolf, J., Seto, T., Doebele, R., Kapre, A., Chen, D., McCallum, S., Osborne, S. and Demetri, G. (2021). Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours. ESMO Open, 6 (3). AMSTERDAM: ELSEVIER. ISSN 2059-7029
Smeltzer, M., Bunn, B., Choi, Y. S., Coate, L., Corona-Cruz, J., Drilon, A., Duma, N., Edelman, M., Fidler, M. J., Gadgeel, S., Goto, Y., Herbst, R., Hesdorffer, M., Higgins, K., Labdi, B., Leal, T., Liu, S., Mazotti, J., Novello, S., Patel, S., Popat, S., Ramirez, R., Reckamp, K., Reguart, N., Soo, R., Tan, A., Wolf, J., Yano, S., Stiles, B. and Baird, A. (2021). The Global Impact of COVID-19 on Telehealth and Care for Persons With Thoracic Cancers. J. Thorac. Oncol., 16 (10). S. S879 - 1. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1556-1380
2020
Barlesi, F., Wolf, J., Ahn, M-J., Doebele, R. C., Paz-Ares, L., Rolfo, C., Siena, S., Seto, T., Ohe, Y., Ou, S. H. I., Krebs, M. G., Kapre, A., Piault-Louis, E., McCallum, S., Osborne, S., Aziez, A. and Drilon, A. (2020). Patient reported outcomes (PROs) analysis for patients with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC) receiving entrectinib in the global phase II STARTRK-2 study. Ann. Oncol., 31. S. S1391 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Drilon, A., Oxnard, G. R., Tan, D. S. W., Loong, H. H. F., Johnson, M., Gainor, J., McCoach, C. E., Gautschi, O., Besse, B., Cho, B. C., Peled, N., Weiss, J., Kim, Y. -J., Ohe, Y., Nishio, M., Park, K., Patel, J., Seto, T., Sakamoto, T., Rosen, E., Shah, M. H., Barlesi, F., Cassier, P. A., Bazhenova, L., De Braud, F., Garralda, E., Velcheti, V., Satouchi, M., Ohashi, K., Pennell, N. A., Reckamp, K. L., Dy, G. K., Wolf, J., Solomon, B., Falchook, G., Ebata, K., Nguyen, M., Nair, B., Zhu, E. Y., Yang, L., Huang, X., Olek, E., Rothenberg, S. M., Goto, K. and Subbiah, V. (2020). Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer. N. Engl. J. Med., 383 (9). S. 813 - 825. WALTHAM: MASSACHUSETTS MEDICAL SOC. ISSN 1533-4406
Drilon, A., Paz-Ares, L., Doebele, R. C., Farago, A. F., Liu, S. V., Chawla, S. P., Tosi, D., Blakely, C. M., Krauss, J. C., Bazhenova, L., John, T., Besse, B., Wolf, J., Seto, T., Cho, B. C., Rolfo, C., Osborne, S., Aziez, A. and Demetri, G. D. (2020). Entrectinib in NTRK fusion-positive NSCLC: Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001. Ann. Oncol., 31. S. S474 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Dziadziuszko, R., Siena, S., Tan, D. S. W., Cho, B. C., Ahn, M-J., Goto, K., Garrido-Lopez, P., Farago, A. F., Loong, H. H. F., Tosi, D., John, T., Wolf, J., Chiu, C-H., Liu, S. V., Patel, M. R., Drilon, A., Pitcher, B., Simmons, B. and Doebele, R. C. (2020). Efficacy of entrectinib in patients with NTRK or ROS1 fusion-positive NSCLC with CNS metastases at baseline. Ann. Oncol., 31. S. S833 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Loong, H. H. F., Goto, K., Elamin, Y. Y., Solomon, B., Santini, F. C., Soldatenkova, V., Sashegyi, A., Lin, A. Bence, Lin, B. K., Wolf, J., Oxnard, G. R., Zhou, C., Drilon, A. and Park, K. (2020). LIBRETTO-431: Selpercatinib in treatment (Tx)-naive patients with RET fusion-positive (RET plus ) non-small cell lung cancer (NSCLC). Ann. Oncol., 31. S. S893 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
2018
Doebele, R., Ahn, M., Siena, S., Drilon, A., Krebs, M., Lin, C., De Braud, F., John, T., Tan, D., Seto, T., Dziadziuszko, R., Arkenau, H., Barlesi, F., Rolfo, C., Wolf, J., Chow-Maneval, E., Multani, P., Cui, N., Riehl, T. and Cho, B. C. (2018). Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small Cell Lung Cancer (NSCLC). J. Thorac. Oncol., 13 (10). S. S321 - 2. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1556-1380